Posted by Michael Wonder on 18 May 2020
Health economic assessment of Bavencio and Inlyta
18 May 2020 - TLV has developed a health economic assessment for the regions regarding the combination of avelumab (Bavencio) and axitinib (Inlyta) for the first-line treatment of patients with advanced renal cell carcinoma.
TLV believes that the relevant comparison for advanced low risk renal cell carcinoma is Votrient.
For advanced higher risk renal cell carcinoma, TLV's assessment is that the combination of Opdivo plus Yervoy is the relevant comparison.
